Nuchev Limited reported a 4.6% rise in FY26 group sales to $24.1 million, driven by robust domestic Oli6 retail and a stronger Brauer contribution. International sales lagged due to regulatory delays in Vietnam, while practitioner channel revenue remained soft despite new digital initiatives. The company secured a $4 million working capital facility to support growth and product development.
- FY26 group sales revenue up 4.6% to $24.1 million
- Domestic Oli6 retail growth and Brauer supply improvements
- Vietnam regulatory changes delay international revenue
- Practitioner channel soft but supported by new ecommerce site
- $4 million unsecured working capital facility secured
Domestic Retail Drives Revenue Momentum
Nuchev Limited (ASX:NUC) closed FY26 with a 4.6% increase in group sales revenue to $24.1 million, buoyed primarily by strong performance in its domestic Oli6 retail segment. The June 2026 quarter saw a 26.7% jump in revenue year-on-year to $2.9 million, reflecting sustained demand from major grocery and pharmacy chains including Chemist Warehouse, Coles, and Woolworths. Retail scan data confirmed positive brand momentum, underpinning management’s confidence in the domestic market’s resilience where execution and customer support align.
The company also expanded the Oli6 product range beyond infant formula with six new children’s snacking SKUs, two Nighty Night Goat functional food products, and refreshed goat milk powder formats. Supporting this diversification, the launch of the dedicated Oli6Goat.com website in June 2026 created a digital platform for non-infant formula offerings, signalling Nuchev’s intent to broaden its foothold in goat nutrition.
International Sales Hampered by Vietnam Regulatory Uncertainty
International revenue remained subdued, primarily due to delays in Vietnam where evolving product registration frameworks have created uncertainty around compliance and launch timing. Nuchev is actively collaborating with local partners to clarify regulatory requirements and progress registration and import documentation. While this has postponed order conversion for select products, the company maintains a positive long-term view on international opportunities, aiming to translate these into more consistent revenue streams once regulatory hurdles are cleared.
Practitioner Channel Softness Tempered by Digital Advances
The practitioner channel continued to underperform, reflecting softer trading conditions and reduced distributor purchasing around the financial year-end. However, BioPractica; the company’s practitioner-facing brand; showed signs of gaining traction, particularly in New Zealand during June 2026. The launch of a new BioPractica ecommerce website marked a strategic shift toward a direct B2B sales model, consolidating multiple brands and aiming to improve distributor execution and sales consistency. Nuchev plans to build on this foundation by expanding product ranges and increasing active practitioner accounts.
Brauer Contribution Strengthens Amid Supply Improvements
Brauer, distributed exclusively by Nuchev in Australia, delivered a stronger contribution in the final quarter, aided by improved supply chains and recovery from earlier stock shortages. The distribution model remains central to Nuchev’s strategy to scale across health, wellness, and beauty categories, providing greater control over brand execution and customer engagement. However, this approach also increases working capital demands, prompting careful management of inventory and receivables as the business expands.
Working Capital Facility Enhances Financial Flexibility
In July 2026, Nuchev secured a $4 million unsecured working capital facility from substantial shareholders H&S International, drawing $1.5 million during the quarter. This facility, carrying an average interest rate of 12%, is designed to support ongoing growth initiatives including product development, inventory investment, and channel expansion. At quarter-end, cash on hand stood at $2.1 million, with management maintaining disciplined cashflow and working capital oversight to align inventory and supplier payments with customer demand.
Strategic Focus on Execution and Profitability
CEO Nathan Cheong emphasised the importance of disciplined execution and cash management as Nuchev transitions into FY27. While domestic retail and Brauer’s contributions provide a solid base, international and practitioner channels require further work to stabilise revenue. The company’s FY27 budget process and strategic planning continue to prioritise revenue growth, improved conversion, and working capital efficiency with an overarching aim to move toward profitability over time.
Bottom Line?
Nuchev’s solid domestic retail growth and enhanced working capital position set the stage for FY27, but international regulatory challenges and practitioner channel softness remain key hurdles to watch.
Questions in the middle?
- How quickly will Nuchev resolve Vietnam’s regulatory uncertainties to unlock international revenue?
- Can the new BioPractica ecommerce platform translate into sustained practitioner channel growth?
- Will working capital demands from the distribution model constrain Nuchev’s expansion plans?